Ekaterina Trofimova
send message
Education
|
||
Experience
|
||
Languages
|
| ||
- “2-Morpholino-5-Phenyl-6H-1,3,4-Thiadiazine Corrects Metabolic Disorders during the Development of Alloxan Diabetes Mellitus in Rats” (Bulletin of Experimental Biology and Medicine,
No. 1, November, 2016. (co-authored withV. Emelianov, L. Sidorova, T. Tseitler, I. Gette, T. Bulavintseva, S. Smirnykh, N. Maksimova, N. Mochulskaya, O. Chupakhin, V. Chereshnev) - “Atomic-powered microscopy of erythrocytes and metabolic disturbances in experimental diabetes mellitus and its correction by lipoic acid” (Biophysics, 2016, Issue 5 (co-authored with
V. Emelyanov, D. Leontiev, A. Ishchenko, T. Bulavintseva, I. Danilova) - “Synthesis of new 1,3,4-thiadiazines and their ability to inhibit non-enzymatic glycosylation of proteins” (Khimiko-Farmatsevticheskii Zhurnal, 2015,
No. 8. (co-authored withL. Sidorova, T. Tseitler, N. Perova, V. Emelyanov, N. Maksimova, N. Mochulskaya, V. Chereshnev, O. Chupakhin) - “Synthesis of new 1,3,4-thiadiazines capable of inhibiting nonenzymatic glycosylation of proteins” (Pharmaceutical Chemistry Journal,
No. 8, November, 2015. (co-authored withL. Sidorova, T. Tseitler,N. Perova, V. Emel'yanov, N. Maksimova, N. Mochulskaya, V. Chereshnev, O. Chupakhin) - “Correction of metabolic disorders in alloxan diabetes in
1,3,4-thiadiazine derivatives” (Russian Immunological Journal - 2015.No. 2 (1) (co-authored withV. Emelianov, L. Sidorova, T. Zeitler, T. Bulavintseva, I. Gette, I. Danilova, N. Maksimova, N. Mochulskaya, O. Chupakhin, V. Chereshnev)
- Advising Russian companies on the strategy for acquiring patent protection and the exclusive right to packaging design in Russia, United States, Canada, European Union countries, CIS countries, China, India, South Korea, Mexico, Australia, New Zealand, South Africa, Japan, Brazil.